Arlington, MA, United States of America

Adam Brockman

USPTO Granted Patents = 1 

Average Co-Inventor Count = 3.0

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2024

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Adam Brockman: Innovator in Pharmaceutical Formulations

Introduction

Adam Brockman is a notable inventor based in Arlington, MA (US). He has made significant contributions to the field of pharmaceuticals, particularly in the development of formulations that address various diseases and conditions. His work is characterized by a commitment to improving health outcomes through innovative solutions.

Latest Patents

Adam Brockman holds a patent for "Pharmaceutical formulations and uses thereof." This invention relates to pharmaceutical compositions and unit dosage forms comprising a quinoline compound, or a pharmaceutically acceptable salt thereof. These formulations are particularly useful for the treatment of inflammatory diseases, respiratory diseases, organ diseases, viral infections, and associated conditions such as acute respiratory distress syndrome. He has 1 patent to his name.

Career Highlights

Brockman is currently employed at Aldeyra Therapeutics, Inc., where he continues to advance his research and development efforts. His work at the company focuses on creating innovative therapeutic solutions that can significantly impact patient care.

Collaborations

Throughout his career, Adam has collaborated with notable colleagues, including Todd Brady and Stephen Gitu Machatha. These partnerships have fostered a collaborative environment that enhances the innovation process.

Conclusion

Adam Brockman exemplifies the spirit of innovation in the pharmaceutical industry. His contributions through patents and collaborations highlight his dedication to improving health outcomes. His work continues to inspire advancements in medical treatments.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…